Clostridial toxin derivatives and methods for treating pain

Details Clostridial toxin derivatives and methods for treating pain Clostridial toxin derivatives and methods for treating pain

2007-07-17

2007-07-17

Kam, Chih-Min (Department: 1656)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S236100, C435S069700, C435S320100, C435S325000, C530S350000, C514S002600, C514S012200, C536S023700

Reexamination Certificate

active

11265953

ABSTRACT:
Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.

REFERENCES:
patent: 4189426 (1980-02-01), Li
patent: 4481139 (1984-11-01), Folkers et al.
patent: 4664911 (1987-05-01), Uhr et al.
patent: 4719231 (1988-01-01), Umezawa et al.
patent: 5410019 (1995-04-01), Coy et al.
patent: 5714468 (1998-02-01), Binder
patent: 5744131 (1998-04-01), Edwards et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5846216 (1998-12-01), Gonzales et al.
patent: 5861284 (1999-01-01), Nishimura et al.
patent: 5891842 (1999-04-01), Kream
patent: 5965406 (1999-10-01), Murphy
patent: 5989545 (1999-11-01), Foster et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: WO95/32738 (1995-07-01), None
patent: 9633273 (1996-10-01), None
patent: 98/01754 (1998-01-01), None
patent: 9807864 (1998-02-01), None
patent: 9917806 (1999-04-01), None
XP001011356, Berge, O-G et al., “Selective Neurotoxic Lesions of Descending Serotonergic and Noradrenergic Pathways in the Rat”; Journal of Neurochemistry; 44(4):1156-1161 (1985).
XP001012206, Benoliel, R et al., “Actions of intrathecal diphtheria toxin-substance P fusion protein on models of persistent pain”; Pain; 79(2-3):243-253 (1999).
XP001011386, Garzon, J et al., “Effect of intrathecal injection of pertusis toxin on substance P norepinephrine and serotonin contents in various neural structures of arthritic rats”; Life Sciences; 47(21):1915-1924 (1990).
XP-000869767, Intracellular Messengers Contributing to Persistent Noclception and Hypersigesia Induced by L-Glutamate and Substance P in the Rat Formalin Pain Model, Terence J. Coderre, and Kiran Yashpal, European Journal of Neuroscience, vol. 6, pp. 1328-1334, 1994.
XP-002091075, Histochemical Localization of Galactose-Containing Glycoconjugates in Sensory Neurons and Their Processes in the Central and Peripheral Nervous System of the Rat, Wolfgang J. Streit, et al., The Journal of Histochemistry and Cytochemistry, vol. 33, No. 10, pp. 1042-1052, 1985.
XP-000857076, Mosaic Structures of Neurotoxins Produced from Clastridium botullnum type C and D organisms, Murtishl et al., Biochimics of Biophysics Acta, 1307 (1996) 123-126.
Ardati, Ali et al.,Interaction of [3H] Orphanin FQ and125I-Tyr14-Orphanin FQ With The Orphanin FQ Receptor: Kinetics and Modulation by Cations and Guanine Nucleotides, 51(5) Mol. Pharmacol. 816-824 (1997).
Butour, Jean Luc et al.,Recognition and Activation of the Opioid Receptor-Like ORL I Receptor by Nociceptin, Nociceptin Analogs and Opioids, 321(1) Eur. J. Pharmacol. 97-103 (1997).
Butour, Jean Luc et al., [Phe1Ψ(CH2-NH)Gly2]Nociceptin-(1-13)-NH2is an Agonist of the Nociceptin(ORLI)Receptor, 349(1) Eur. J. Pharmacol. R5-6 (1998).
Civelli, Oliver et al.,Reverse Physiology: Discovery of the Novel Neuropeptide, Orphanin FQ/Nociceptin, 12(3) Crit. Rev. Neurobiol. 163-176 (1998).
Lapalu, Sophie et al.,Comparison of the Structure-Activity Relationships of Nociceptin and Dynorphin A using Chimeric Peptides, 417(3) FEBS Lett. 333-336 (1997).
Meunier, Jean Claude et al.,Isolation and Structure of the Endogenous Agonist of Opioid Receptor-Like ORLI Receptor, 377(6549) Nature 532-535 (1995).
Meunier, Jean Claude,Nociceptin/orphanin FQ and the Opioid Receptor-Like ORLI Receptor, 340(1) Eur. J. Pharmacol. 1-15 (1997).
Nothacker, Hans-Peter et al.,Primary Structure and Tissue Distribution of the Orphanin FQ Precursor, 93(16) Proc. Natl. Acad. Sci. U. S. A. 8677-8682 (1996).
Reinscheid, Rainer K. et al.,Orphanin FQ: A Neuropeptide that Activates an Opioidlike G Protein-Coupled Receptor, 270(5237) Science 792-794 (1995).
Reinscheid, Rainer K. et al.,Structure-Activity Relationship Studies on the Novel Neuropeptide Orphanin FQ, 271(24) J. Biol. Chem. 14163-14168 (1996).
Reinscheid, Rainer K. et al.,Structures that Delineate Orphanin FQ and Dynorphin A Pharmacological Selectivities, 273(3) J. Biol. Chem. 1490-1495 (1998).
Shimohigashi, Yasuyuki et al.,Sensitivity of Opioid Receptor-Like Receptor ORLI for Chemical Modification on Nociceptin, a Naturally Occuring Nociceptive Peptide, 271(39) J. Biol. Chem. 23642-23645 (1996).
Ueda, Hiroshi, In vivoMolecular Signal Transduction of Peripheral Mechanisms of Pain, 79(3) Jpn. J. Pharmacol. 263-268 (1999).
Ueda, “In Vivo Molecular Signal Transduction . . . ” Jpn J Pharmacol. vol. 79, 1999, pp. 263-268, English abstract only.
Nichols et al, “Transmission of Chronic Nociception . . . ” Science, vol. 286, Nov. 1999, pp. 1558-1561.
Lopes & Couture, “Localization of Bradykinin-Like . . . ” Neuroscience, vol. 78, 1997, pp. 481-497, Englis abstract only.
Vigna et al, “Characterization of Antibodies . . . ” J Nerosci, vol. 14, 1994, pp. 834-845, English abstract only.
Principles of Neural Science Third Edition, Edited by Kandel et al, p. 395, 1992.
Babenko et al, “Experimental Human Muscle Pain . . . ” Pain, vol. 82, 1999, pp. 1-8.
Garrison & Rall, “Autacoids; Drug Therapy of Inflammation” in Goodman & Gilman's Pharmacological Basis of Therapeutics (Eighth Ed.) (Editors: Gilman, Rall, Nies & Taylor) p. 574-599 (1990).
Henry, “Substance P and Inflammatory . . . ” Disease Therapy, 1993, p. 75-87.
Tsuda et al “In vivo Pathway . . . ” Br J Pharmacol, vol. 127, 1999, pp. 449-456.
Welch et al, “Sensitivity of Emryonic Rat . . . ”Toxicon, vol. 38, 2000, pp. 245-258.
Mathias et al, “Topical Casaicin For Chronic Neck Pain..” Abstract,American Journal of Physical Medicine &Rehabilitation,vol. 74,1995,pp. 39-44.
Furst, “Transmitters Involved in Antinociception in the Spinal Cord” Abstract, Brain Research Bulletin, vol. 48, 1999, pp. 129-141.
Poulain et al, Inhibition of Transmitter Release By Botulinum Neurotoxin A Eur.J.Biochem, vol. 185, 1989, pp. 197-203.
van Hagen et al, “Neuropeptides and Their Receptors” The Finnish Medical Society Duodeam, Ann Med, vol. 31 SUPPL2, pp. 15-22 (1992).

Affiliated with

Also associated with

Rating

Clostridial toxin derivatives and methods for treating pain does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Clostridial toxin derivatives and methods for treating pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Clostridial toxin derivatives and methods for treating pain will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3753526